Scientific article
OA Policy
English

Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?

Published inHepatology International, vol. 12, no. 1, p. 17-25
Publication date2018
Abstract

One to three per cent of the world's population has hepatitis C virus (HCV) infection, which is not only a major cause of liver disease and cancer but also associated with an increased risk of atherosclerosis, despite an ostensibly favourable lipid profile. Autoantibodies are frequent in HCV infection and emerging evidence shows that autoantibodies could be valuable for cardiovascular disease (CVD) risk stratification. This study investigated a novel independent biomarker of CVD, autoantibodies to apolipoprotein A-1 (anti-apoA-1 IgG) and lipids in patients with chronic HCV before, during and after direct-acting anti-viral (DAA) therapy.

Citation (ISO format)
BRIDGE, Simon H et al. Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis? In: Hepatology International, 2018, vol. 12, n° 1, p. 17–25. doi: 10.1007/s12072-018-9842-5
Main files (1)
Article (Published version)
Identifiers
Journal ISSN1936-0533
415views
205downloads

Technical informations

Creation22/08/2018 10:32:00
First validation22/08/2018 10:32:00
Update time23/01/2025 11:31:53
Status update23/01/2025 11:31:53
Last indexation23/01/2025 11:39:54
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack